Compare AstraZeneca plc (AZN) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Union Pacific Corporation — how do they compare? AstraZeneca plc trades at $158.47 (market cap $248.14B), while Union Pacific Corporation trades at $292.17 (market cap $173.99B). The key difference: AstraZeneca plc is the larger of the two by market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AZN | UNP | |
|---|---|---|
Market Cap | $248.14B | $173.99B |
Sector | Health | Industrials |
52-Week High | $209.48 | $307.32 |
52-Week Low | $147.06 | $214.91 |
Enterprise Value | $275.41B | $203.04B |
Dividend Yield | 2.01% | 1.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Union Pacific (UNP) trades at $294.24, up 0.68% with strong fundamentals including 28.85% net margins and 39.7% ROE. The stock shows bullish momentum with Q2 2026 EPS beating estimates by 4.6% and management raising full-year guidance. Technical indicators are neutral overall, with the current price near resistance at $294. Recent news highlights institutional accumulation and a 3% dividend increase announced July 29, 2026.
Outlook remains positive with analyst consensus target of $334.33 (13.6% upside) and 58.7% buy ratings. Key opportunities include service-led growth driving margin expansion, while risks involve high fuel costs and regulatory scrutiny of the Norfolk Southern merger. The company's strong cash flow generation supports continued dividend growth and capital returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
